In patients with metastatic PrCa, among this gene panel for germline screening, ATM, BRCA1, BRCA2 and potentially other DNA repair genes may inform response to PARP inhibitors [296,305,306], BRCA1, BRCA2 and other DNA repair genes sensitivity to platinum chemotherapy [307,308], and DNA mismatch repair genes response to anti-PD-1 immunotherapy [309,310]. Here, BRCA1 is linked to pure red-cell aplasia.